BREAST
CANCER RISK ASSESSMENT |
| The second Breast
Cancer Prevention Trial conducted by the National Surgical Breast and Bowel Project
(NSABP) and sponsored by the National Cancer Institute (NCI) is set to begin shortly. The
Study of Tamoxifen And
Raloxifene (STAR) trial will determine how tamoxifen (Nolvadex) and raloxifene
(Evista) compare to each other as agents for breast cancer risk-reduction while evaluating
the side effects of both drugs. To be eligible to participate in the trial, a woman must be at increased risk for developing breast cancer. Risk category (average, somewhat-higher-than-average, and high-risk) is determined based on results of a risk assessment questionnaire completed by women who think they may be candidates for the STAR trial. This risk assessment tool takes certain risk factors into consideration that when combined, are thought to be associated with increased risk for developing breast cancer. To find out more information about the STAR trial, and/or breast cancer risk assessment, contact: Thomas Jefferson University
Phone: 215-955-1011 |
Revised:August 13, 2003. URL: http://www.kcc.tju.edu/HereditaryCancer/BreastCancer.htm
|
| |
| PLEASE
NOTE: The Kimmel Cancer Center Web site, its content and programs, is provided for informational and educational purposes only and is not intended as medical advice, nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff. |
|
| Please send comments to: webmaster@kimmelcancercenter.org. All contents copyright © 2002 Thomas Jefferson University. All rights reserved. | |
|
|
